賴峻毅實驗室
Cancer Biology meets Precision Medicine
Our laboratory studies breast cancer, particularly hormone-positive (HR+) subtypes, which comprise approximately 70% of breast cancer cases. Metastatic HR+ breast cancer has a median survival of around 5 years post-diagnosis. Current treatment approaches include endocrine therapy (tamoxifen, fulvestrant, aromatase inhibitors), CDK4/6 inhibitors, and PIK3CA/AKT/mTOR pathway agents.
We investigate the Hippo pathway and its role in breast cancer resistance mechanisms. Key pathway components include MST1/2, LATS1/2 kinases, and YAP/TAZ effector proteins.
We discovered a previously unknown relationship between the Hippo pathway and CDK7, demonstrating potential reversal of CDK4/6 inhibitor resistance in hormone-positive breast cancer.
Research on the CDK6 D224Y mutation and its role in resistance mechanisms, involving mass spectrometry proteomics approaches to uncover novel protein interactions.
Investigation of mechanisms regulating endocytosis and ADC internalization, aiming to improve therapeutic efficacy of next-generation antibody-drug conjugates.